Home/Pipeline/Next-Gen MIGS Devices

Next-Gen MIGS Devices

Glaucoma

DevelopmentActive

Key Facts

Indication

Glaucoma

Phase

Development

Status

Active

Company

Glaukos

About Glaukos

Glaukos Corporation's mission is to develop and lead the global ophthalmic market with novel therapies that advance the standard of care for chronic eye diseases. The company has achieved a paradigm shift in glaucoma treatment through its market-leading MIGS platform, with over 3 million iStent device implants, and is expanding into corneal and retinal therapeutics. Its strategy leverages a deep commitment to R&D—reinvesting ~30% of sales—to build a robust pipeline of micro-invasive devices and sustained-drug delivery systems, aiming to own the entire treatment continuum in key ophthalmic segments.

View full company profile

Therapeutic Areas

Glaucoma Corneal Disorders Retinal Diseases

Other Glaucoma Drugs

Drug	Company	Phase	Status
INM-088	InMed Pharmaceuticals	Preclinical	Active
ANX007	Annexon Biosciences	Phase 2	Active
PER-001	Perfuse Therapeutics	Phase 2	Active
hOTX2	BrainEver	Discovery	Active
Glaucoma Treatment	BVI Medical	Commercial	Active
MediPrint Lens (Glaucoma)	MediPrint Ophthalmics	Phase 2b	Active
Glaucoma Program	Broadwing Bio	Pre-clinical	Active
MSC Exosomal Eye Serum	Vitti Labs	Pre-clinical	Active
BTQ1902	Betaliq	Phase 2	Active
TODDD™ Platform	Amorphex Therapeutics	Pre-clinical	Active
Glaucoma Diagnostics	Avellino Laboratories	Development/Accreditation	Active
Glaucoma Portfolio	Visufarma	Commercial	Active